Earlier Risk Detection

Advances in genetics, imaging, biomarkers, and psychosocial metrics offer new opportunities to detect cardiovascular risk well before symptoms emerge. Traditional risk assessment models based on short-term outcomes often overlook these early signals.

This focus area of the PRIME-Heart Initiative redefines risk assessment during the critical decades of adulthood (ages 25–65), aiming to support timely identification and intervention that deliver lifelong cardiovascular benefit.

A multidisciplinary Roundtable will launch this focus area, bringing together experts across fields to examine emerging evidence and identify actionable strategies. Insights from this meeting will guide the development of clinical guidance as well as clinician and patient-facing resources designed to support earlier, more personalized approaches to cardiovascular risk detection.

• Advanced Cardiovascular Risk Detection for the Critical Decades Roundtable

← Back

The PRIME-Heart Initiative is supported by:
Amgen, AstraZeneca, HeartFlow, Novartis, Novo Nordisk